Stratec SE

RSS Feed
STRATEC Biomedical designs and manufactures automation solutions and technologies for use mainly in in-vitro diagnostics (IVD) and in other regulated markets. IVD refers to those diagnostics activities performed outside the body in a glass or in test receptacles in a laboratory. Co. operates through two segments: Instrumentation and All Other. In the Instrumentation segment, Co. designs and manufactures fully automated analyzer systems for its clinical diagnostics and biotechnology customers. In its all other segment, Co. develops workflow software for networking several analyzer systems and develops and sells scientific materials and technologies such as nucleic acid purification.
  • TickerSBS
  • ISINDE000STRA555
  • SectorHealth Care Equipment & Services
  • CountryGermany
EQS Group AG

DGAP-News: STRATEC SE BENENNT NEUE AUFSICHTSRATSVORSITZENDE

DGAP-News: STRATEC SE / Schlagwort(e): Personalie STRATEC SE BENENNT NEUE AUFSICHTSRATSVORSITZENDE 26.11.2020 / 16:19 Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. STRATEC SE BENENNT NEUE AUFSICHTSRATSVORSITZENDE Birkenfeld, 26. November 2020 Der Aufsichtsrat der STRATEC SE hat in seiner heutigen Sitzung Frau Prof. Dr. Stefanie Remmele mit Wirkung zum 26. November 2020 zur neuen Aufsichtsratsvorsitzenden gewählt. Frau Prof. Dr. Remmele ist Professorin für Medizintechnik an der Hochschule für angewandte Wissenschaften Landshut und seit 2014 M...

Free
Corporate Voice
Health Care
Stratec SE
53d 26/11/2020 1 DE
EQS Group AG

DGAP-News: STRATEC SE APPOINTS NEW SUPERVISORY BOARD CHAIR

DGAP-News: STRATEC SE / Key word(s): Personnel STRATEC SE APPOINTS NEW SUPERVISORY BOARD CHAIR 26.11.2020 / 16:19 The issuer is solely responsible for the content of this announcement. STRATEC SE APPOINTS NEW SUPERVISORY BOARD CHAIR Birkenfeld, November 26, 2020 At its meeting today, the Supervisory Board of STRATEC SE elected Prof. Dr. Stefanie Remmele as the new Chairwoman of the Supervisory Board as of November 26, 2020. Prof. Dr. Remmele is Professor of Medical Technology at Landshut University of Applied Sciences and has been a member of the Supervisory Board at STRA...

Free
Corporate Voice
Health Care
Stratec SE
53d 26/11/2020 1 EN
TheScreener

STRATEC BIOMEDICAL AG suffers a double requalification, which weighs heavily on its rating, now at Slightly Negative.

The independent financial analyst theScreener just downgraded the general evaluation of STRATEC BIOMEDICAL AG (DE), active in the Medical Equipment industry. As regards its fundamental valuation, the title loses a star(s) and now shows 0 out of 4 stars. Its market behaviour is also negatively reassessed and may be considered as moderately risky. theScreener believes that this double requalification keeps the title under pressure and justifies an overall rating downgrade to Slightly Negative. As of the analysis date November 10, 2020, the closing price was EUR 101.60 and its target price was es...

EUR 12.43
Quant
Health Care
Stratec SE
68d 11/11/2020 6 EN
EQS Group AG

DGAP-News: STRATEC MIT ZWEISTELLIGEN WACHSTUMSRATEN BEI UMSATZ UND ERGEBNIS IN DEN ERSTEN NEUN MONATEN 2020

DGAP-News: STRATEC SE / Schlagwort(e): Quartalsergebnis/Quartals-/Zwischenmitteilung STRATEC MIT ZWEISTELLIGEN WACHSTUMSRATEN BEI UMSATZ UND ERGEBNIS IN DEN ERSTEN NEUN MONATEN 2020 05.11.2020 / 06:55 Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. STRATEC MIT ZWEISTELLIGEN WACHSTUMSRATEN BEI UMSATZ UND ERGEBNIS IN DEN ERSTEN NEUN MONATEN 2020 - Umsatzerlöse 9M/2020 steigen gegenüber Vorjahr um 13,1% auf 179,1 Mio. € (9M/2019: 158,3 Mio. €) - Adjustiertes EBIT 9M/2020 erhöht sich um 40,7% auf 28,1 Mio. € (9M/2019: 20,0 Mio. €) - Adjustierte EBI...

Free
Corporate Voice
Health Care
Stratec SE
74d 05/11/2020 1 DE
EQS Group AG

DGAP-News: STRATEC WITH DOUBLE-DIGIT GROWTH IN SALES AND EARNINGS IN FIRST NINE MONTHS OF 2020

DGAP-News: STRATEC SE / Key word(s): Quarter Results/Quarterly / Interim Statement STRATEC WITH DOUBLE-DIGIT GROWTH IN SALES AND EARNINGS IN FIRST NINE MONTHS OF 2020 05.11.2020 / 06:55 The issuer is solely responsible for the content of this announcement. STRATEC WITH DOUBLE-DIGIT GROWTH IN SALES AND EARNINGS IN FIRST NINE MONTHS OF 2020 - Sales in 9M/2020 rise year-on-year by 13.1% to € 179.1 million (9M/2019: € 158.3 million) - Adjusted EBIT in 9M/2020 up 40.7% to € 28.1 million (9M/2019: € 20.0 million) - Adjusted EBIT margin improves year-on-year by 310 basis points t...

Free
Corporate Voice
Health Care
Stratec SE
74d 05/11/2020 1 EN
EQS Group AG

DGAP-News: STRATEC SE BENENNT NEUE AUFSICHTSRATSVORSITZENDE

DGAP-News: STRATEC SE / Schlagwort(e): Personalie STRATEC SE BENENNT NEUE AUFSICHTSRATSVORSITZENDE 26.11.2020 / 16:19 Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. STRATEC SE BENENNT NEUE AUFSICHTSRATSVORSITZENDE Birkenfeld, 26. November 2020 Der Aufsichtsrat der STRATEC SE hat in seiner heutigen Sitzung Frau Prof. Dr. Stefanie Remmele mit Wirkung zum 26. November 2020 zur neuen Aufsichtsratsvorsitzenden gewählt. Frau Prof. Dr. Remmele ist Professorin für Medizintechnik an der Hochschule für angewandte Wissenschaften Landshut und seit 2014 M...

Free
Corporate Voice
Health Care
Stratec SE
53d 26/11/2020 1 DE
EQS Group AG

DGAP-News: STRATEC SE APPOINTS NEW SUPERVISORY BOARD CHAIR

DGAP-News: STRATEC SE / Key word(s): Personnel STRATEC SE APPOINTS NEW SUPERVISORY BOARD CHAIR 26.11.2020 / 16:19 The issuer is solely responsible for the content of this announcement. STRATEC SE APPOINTS NEW SUPERVISORY BOARD CHAIR Birkenfeld, November 26, 2020 At its meeting today, the Supervisory Board of STRATEC SE elected Prof. Dr. Stefanie Remmele as the new Chairwoman of the Supervisory Board as of November 26, 2020. Prof. Dr. Remmele is Professor of Medical Technology at Landshut University of Applied Sciences and has been a member of the Supervisory Board at STRA...

Free
Corporate Voice
Health Care
Stratec SE
53d 26/11/2020 1 EN
EQS Group AG

DGAP-News: STRATEC MIT ZWEISTELLIGEN WACHSTUMSRATEN BEI UMSATZ UND ERGEBNIS IN DEN ERSTEN NEUN MONATEN 2020

DGAP-News: STRATEC SE / Schlagwort(e): Quartalsergebnis/Quartals-/Zwischenmitteilung STRATEC MIT ZWEISTELLIGEN WACHSTUMSRATEN BEI UMSATZ UND ERGEBNIS IN DEN ERSTEN NEUN MONATEN 2020 05.11.2020 / 06:55 Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. STRATEC MIT ZWEISTELLIGEN WACHSTUMSRATEN BEI UMSATZ UND ERGEBNIS IN DEN ERSTEN NEUN MONATEN 2020 - Umsatzerlöse 9M/2020 steigen gegenüber Vorjahr um 13,1% auf 179,1 Mio. € (9M/2019: 158,3 Mio. €) - Adjustiertes EBIT 9M/2020 erhöht sich um 40,7% auf 28,1 Mio. € (9M/2019: 20,0 Mio. €) - Adjustierte EBI...

Free
Corporate Voice
Health Care
Stratec SE
74d 05/11/2020 1 DE
EQS Group AG

DGAP-News: STRATEC WITH DOUBLE-DIGIT GROWTH IN SALES AND EARNINGS IN FIRST NINE MONTHS OF 2020

DGAP-News: STRATEC SE / Key word(s): Quarter Results/Quarterly / Interim Statement STRATEC WITH DOUBLE-DIGIT GROWTH IN SALES AND EARNINGS IN FIRST NINE MONTHS OF 2020 05.11.2020 / 06:55 The issuer is solely responsible for the content of this announcement. STRATEC WITH DOUBLE-DIGIT GROWTH IN SALES AND EARNINGS IN FIRST NINE MONTHS OF 2020 - Sales in 9M/2020 rise year-on-year by 13.1% to € 179.1 million (9M/2019: € 158.3 million) - Adjusted EBIT in 9M/2020 up 40.7% to € 28.1 million (9M/2019: € 20.0 million) - Adjusted EBIT margin improves year-on-year by 310 basis points t...

Free
Corporate Voice
Health Care
Stratec SE
74d 05/11/2020 1 EN
EQS Group AG

DGAP-News: STRATEC MIT DEUTLICHEM UMSATZWACHSTUM SOWIE GESTEIGERTER PROFITABILITÄT IM ERSTEN HALBJAHR 2020

DGAP-News: STRATEC SE / Schlagwort(e): Halbjahresergebnis/Prognoseänderung STRATEC MIT DEUTLICHEM UMSATZWACHSTUM SOWIE GESTEIGERTER PROFITABILITÄT IM ERSTEN HALBJAHR 2020 13.08.2020 / 06:55 Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. STRATEC MIT DEUTLICHEM UMSATZWACHSTUM SOWIE GESTEIGERTER PROFITABILITÄT IM ERSTEN HALBJAHR 2020 - Änderung der Finanzprognose 2020 unter Berücksichtigung der COVID-19-Pandemie: Organisches Umsatzwachstum von 14,0% bis 18,0% und adj. EBIT-Marge von etwa 15,5% bis 16,5% erwartet - Hoher zusätzlicher Bedarf...

Free
Corporate Voice
Health Care
Stratec SE
158d 13/08/2020 1 DE
Edison Investment Research
Sean Conroy

Stratec - Strong sales growth helped by COVID-19

Stratec SE is a highly regarded German company that designs, develops and supplies about 8,000 fully automated diagnostics systems and modules annually. Clients include major companies like Hologic, DiaSorin and Siemens Healthineers. Typical 12–15-year product life cycles give underlying stability. Stratec is benefiting from COVID-19 driven diagnostic demand. H120 sales were €119.4m, up 9.9% y-o-y, with a 15.4% adjusted EBIT margin. The company guides to FY20 revenue growth of 14–18% with a 15.5–16.5% adjusted EBIT margin.

Equity
Health Care
Stratec SE
91d 19/10/2020 2 EN
Oddo BHF
Alexander Rummler ...
  • Manuel Martin, CEFA,CREA

ODDO BHF GERMAN MORNING NEWS – DETAILED COMMENTS 08.15.2018

...

Equity
Industrial Goods & Services
LEO , G24 ...
2y 15/08/2018 18 EN
Oddo BHF

STRATEC Biomedical AG : Downgrade to Reduce after weak H1 results and revised outlook for 2018

>Weak H1 2018 results miss our estimates - Stratec published H1 18 results. Consolidated sales fell 10.5% (nominally) to € 90.2m (Oddo BHFe: € 96.1m; H1 2017: € 51.2m). Organically, sales declined 3.9% yoy. Note that the nominal sales decline of 10.5% includes exchange rate effects and the first-time adoption of IFRS 15 each of each negatively impacted sales growth by 3.3pp.H1 2018 adj. EBIT fell 31% yoy to € 8.9m (Oddo BHFe: € 11.2m, H1 2017: € 12.8m). The adj. ...

Equity
Health Care
Stratec SE
2y 15/08/2018 4 EN
Edison Investment Research

Update: Excellent strategic fit with integrated consumables

Stratec, a designer and builder of automated OEM diagnostic systems, has announced its intention to acquire an Austrian business that designs and manufactures complex precision consumables for high-end biomedical and diagnostic systems. This is an excellent strategic fit as it will allow Stratec to integrate high-value consumables into system designs and accumulate recurring revenues: Stratec expects a 20% CAGR to 2020 on DADC 2015 sales of €17m. Stratec is experiencing reduced Chinese orders and the guided 5% EBIT of DADC may lower the 2017 EBIT margin to 17%.

Equity
Health Care
Stratec SE
4y 15/06/2016 3 EN
Edison Investment Research

Update: Hungary Haematology offsets Chinese famine

Stratec, a German designer and builder of automated OEM diagnostic systems, has revised its core business guidance for 2016 and 2017 due to volatile client forecasts arising from sales uncertainty and local competition in China. Preliminary 2015 results showed revenues up 1.4% to €146.9m and an improved EBIT margin of 18.3% due to higher service part sales. The about €67m Diatron acquisition adds about €25m revenue in FY16 and €37m in FY17, taking our 2016 consolidated revenue forecast to a revised €176m, with 2017 revenues potentially at €198m. Diatron’s EBIT margin is assumed t...

Equity
Health Care
Stratec SE
4y 04/04/2016 7 EN
TheScreener

STRATEC BIOMEDICAL AG suffers a double requalification, which weighs heavily on its rating, now at Slightly Negative.

The independent financial analyst theScreener just downgraded the general evaluation of STRATEC BIOMEDICAL AG (DE), active in the Medical Equipment industry. As regards its fundamental valuation, the title loses a star(s) and now shows 0 out of 4 stars. Its market behaviour is also negatively reassessed and may be considered as moderately risky. theScreener believes that this double requalification keeps the title under pressure and justifies an overall rating downgrade to Slightly Negative. As of the analysis date November 10, 2020, the closing price was EUR 101.60 and its target price was es...

EUR 12.43
Quant
Health Care
Stratec SE
68d 11/11/2020 6 EN
Ford Equity Research

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the we...

EUR 18.48
Quant
Health Care
Stratec SE
4y 23/12/2016 2 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch